文献速递骨肌神经介入CTMR

经皮射频消融治疗脊柱骨转移瘤的并发症:8年单中心经验

Complications of Percutaneous Radiofrequency Ablation of Spinal Osseous Metastases: An 8-Year Single-Center Experience.
PubMed 文献 · AJR Am J Roentgenol · 2021-03-31

该回顾性单中心研究纳入166例连续患者共266个脊柱转移瘤,评估射频消融联合椎体增强术的并发症。总并发症率3.0%,主要并发症率0.4%,局部肿瘤控制率78.9%,各随访时间点疼痛缓解均具统计学意义(p < .001)。结论认为该技术安全性良好。

要点

  • 总并发症率3.0%,主要并发症率仅0.4%,安全性较高。
  • 主要并发症为脊髓静脉梗死致下肢无力、排尿困难及勃起不能。
  • 术后各时间点疼痛缓解均显著(p < .001),局部控制率78.9%。

核心结论

  • 射频消融联合椎体增强术治疗脊柱骨转移瘤的总并发症率为3.0%,主要并发症率为0.4%,安全性良好。
  • 局部肿瘤控制率为78.9%,术后各随访时间点疼痛缓解均具统计学显著性(p < .001)。

研究设计与样本

  • 回顾性、符合HIPAA的单中心研究,纳入2012年1月至2019年8月间166例连续患者的266个脊柱转移瘤。
  • 所有患者接受射频消融联合椎体增强术,采用CTCAE标准将并发症分为主要(3-4级)和次要(1-2级)。
  • 疼痛评估采用简明疼痛量表(Brief Pain Inventory)于术后1周、1个月、3个月和6个月进行。
  • 统计方法采用Wilcoxon符号秩检验和Mann-Whitney U检验。

关键影像表现/征象

  • 主要并发症(CTCAE 3级)表现为脊髓静脉梗死导致的下肢无力、排尿困难和勃起不能。
  • 次要并发症包括围手术期短暂神经根痛(4例,CTCAE 2级)、延迟性椎体继发骨折(1例,CTCAE 2级)和随访影像示无症状脊髓水肿(2例,CTCAE 1级)。

诊断标准与关键数值

  • 并发症分级采用常见不良事件评价标准(CTCAE):主要并发症为3-4级,次要并发症为1-2级。
  • 总并发症率3.0%(8/266),主要并发症率0.4%(1/266),次要并发症率2.6%(7/266)。
  • 局部肿瘤控制率为78.9%。
  • 疼痛缓解在所有术后随访时间点均具统计学意义(p < .001)。

临床应用与阅片要点

  • 阅片时需关注术后是否出现脊髓水肿、椎体新发骨折等并发症征象。
  • 报告应描述消融区域及椎体增强后的影像变化,并提示临床关注神经功能症状。
  • 对于术后出现下肢无力、排尿困难等表现,需警惕脊髓静脉梗死等罕见严重并发症。

局限性

  • 本研究为单中心回顾性设计,可能存在选择偏倚。
  • 样本量有限(166例患者,266个肿瘤),罕见并发症的评估可能受限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE. The purpose of this article was to evaluate the complication rate of percutaneous radiofrequency ablation of spinal osseous metastases. MATERIALS AND METHODS. This retrospective HIPAA-compliant study reviewed complications of radiofrequency ablation combined with vertebral augmentation performed on 266 tumors in 166 consecutive patients for management of vertebral metastases between January 2012 and August 2019. Common Terminology Criteria for Adverse Events (CTCAE) was used to categorize complications as major (grade 3-4) or minor (grade 1-2). Local tumor control rate as well as pain palliation effects evaluated by the Brief Pain Inventory scores determined 1 week, 1 month, 3 months, and 6 months after treatment were documented. Wilcoxon signed rank and Mann-Whitney U tests were used for statistical analysis. RESULTS. Among 266 treated tumors, the total complication rate was 3.0% (8/266), the major complication rate was 0.4% (1/266), and the minor complication rate was 2.6% (7/266). The single major (CTCAE grade 3) periprocedural complication was characterized by lower extremity weakness, difficulty in urination, and lack of erection as a result of spinal cord venous infarct. The seven minor complications included four cases of periprocedural transient radicular pain (CTCAE grade 2) requiring transforaminal steroid injections, one case of delayed secondary vertebral body fracture (CTCAE grade 2) requiring analgesics, and two cases of asymptomatic spinal cord edema on routine follow-up imaging (CTCAE grade 1). The local tumor control rate was 78.9%. There were statistically significant pain palliation effects at all postprocedural time intervals (p < .001 for all). CONCLUSION. Radiofrequency ablation of spinal osseous metastases is safe with a 3.0% rate of complications.

来源:AJR Am J Roentgenol,查看原文。版权归原作者所有。

引用

  1. Tomasian A, Marlow J, Hillen TJ, et al. Complications of Percutaneous Radiofrequency Ablation of Spinal Osseous Metastases: An 8-Year Single-Center Experience. AJR Am J Roentgenol. 2021. PMID: 33787296. doi:10.2214/AJR.20.23494

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。